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Abstract
Objective. To determine the relationship between serum vitamin D and markers of subclinical cardiovas-
cular disease (CVD) in patients with SLE.
Methods. We recruited SLE patients (54 ACR 1997 criteria) from outpatient clinics between January 2007
and January 2009. Vitamin D deficiency was defined as serum 25(OH)D <20ng/ml measured by ELISA.
Disease activity was measured using the SLEDAI-2K score. Aortic pulse wave velocity (aPWV) was
measured using PulseTrace 3600 (Micromedical) and carotid plaque (CP) and intimamedia thickness
(IMT) assessed using B-mode Doppler US.
Results. Seventy-five women with SLE were recruited with a median (interquartile range) disease duration
of 16 (827) years. Patients with vitamin D deficiency had higher BMI (P=0.014) and insulin resistance
(P=0.023) than those with 25(OH)D >20ng/ml. Subjects with SLEDAI-2K 54 had lower 25(OH)D than
those with SLEDAI-2K <4 (median 12.9 vs 20.3ng/ml, P=0.031). Aortic stiffness was significantly asso-
ciated with serum 25(OH)D [log(aPWV) b (95% CI) 0.0217 (0.038, 0.005), P=0.010] independently of
BMI, CVD risk factors and serum insulin. Adjustment for disease activity reduced the strength of the
association. There was no association between 25(OH)D and CP or IMT.
Conclusions. Vitamin D deficiency is associated with increased aortic stiffness in SLE, independent of
CVD risk factors and insulin. Increased inflammatory disease activity may be the mechanism by which
vitamin D deficiency mediates vascular stiffness in this patient group.
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Introduction
SLE an autoimmune systemic inflammatory disease
predominantly affecting women. Mortality in SLE has a
bimodal distribution, with a second peak due to cardio-
vascular disease (CVD) [1]. The excess cardiovascular
risk, which may be up to 52 times in SLE, is not explained
by traditional cardiovascular risk factors [24]. The identi-
fication of these novel risk factors is important to ensure
development of targeted therapies to reduce cardiovas-
cular morbidity and mortality in patients with SLE.
Recently, the roles of vitamin D beyond calcium homeo-
stasis have been widely studied. The vitamin D receptor
has been identified in both cells of the immune system
(monocytes, antigen-presenting cells, macrophages, T
cells) and the cardiovascular system (endothelial cells
and vascular smooth muscle cells) [5, 6].
Epidemiological studies within the general population
have demonstrated that vitamin D deficiency is an inde-
pendent risk factor for adverse cardiovascular events
[79]. Furthermore, lower serum 25(OH)D is associated
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Ewith the presence of subclinical CVD, including carotid
IMT, coronary artery calcification and endothelial dysfunc-
tion [1015].
Vitamin D deficiency is more common in patients with
SLE than in age- and gender-matched controls [1619].
This is perhaps unsurprising given that 90% of serum
25(OH)D is obtained from sunlight, and that photosensi-
tivity is a common feature of lupus. Other studies have
also suggested contributions from renal disease and the
use of CSs [17, 2023].
The importance of vitamin D deficiency beyond its role
in bone health in SLE is unclear and is the subject of
current debate [24]. Vitamin D has important immunomo-
dulatory roles in vitro raising the possibility of disease-
specific roles in SLE. Indeed, vitamin D deficiency has
been associated with increased lupus disease activity in
some [18, 20, 25, 26] but not all studies [2731].
If vitamin D deficiency were to contribute to CVD in SLE,
it would represent a readily modifiable novel risk factor.
In this study, we aimed to determine whether vitamin D
deficiency was associated with markers of subclinical
CVD in patients with SLE.
Methods
We recruited SLE patients aged 1870 years from regional
outpatient clinics between January 2007 and January
2009. All patients fulfilled 54 ACR Revised 1997
Classification criteria for SLE. A full clinical history and
physical examination was undertaken in all patients.
Lupus disease activity was measured using the
SLEDAI-2000 scale [32]. Fasting blood samples were
taken for measurement of lipid profiles and glucose,
serum insulin, serum C3 and C4 complement, biochem-
ical profile, full blood count and anti-dsDNA titre. Insulin
resistance was calculated using the homeostatic model
assessment (HOMA-IR) method [33]. Vascular cell ad-
hesion molecules (VCAM-1, E-selectin) were measured
using DuoSet ELISA development kits (R&D Systems,
Abingdon, UK). Serum 25(OH)D and PTH were measured
in randomly selected patients using ELISA. Serum vita-
min D deficiency was defined as 25(OH)D 420ng/ml ac-
cording to regional guidelines (J. Berry, personal
communication). The estimated glomerular filtration rate
(eGFR) was calculated using the Modification of Diet in
Renal Disease (MDRD) equation and normal renal func-
tion was defined as an eGFR>90ml/min/1.73m
2 [34].
Aortic pulse wave velocity (aPWV) was measured using
the automated PulseTrace 3600 (Micro Medical, UK) by
sequentially recording ECG-gated carotid and femoral
artery waveforms as described by Asmar et al. [35].
Briefly, the distance from the sternal notch to the femoral
artery was measured as a straight line between the points
on the body surface using a tape measure. A 4Mhz
Doppler pencil probe was placed at 45 to the skin sur-
face of the artery and measured with the probe facing
towards the flow direction (towards the heart). The
median (IQR) aPWV in a group of healthy female controls
was 4.2 (2.99.2) m/s (S. Haque, personal communica-
tion). Carotid intimamedia thickness (cIMT) and carotid
plaque (CP) were measured using B-mode Doppler US by
an experienced vascular sonographer. The mean carotid
IMT was determined from three separate measurements
on the far wall of the common carotid artery along a sec-
tion 1 cm proximal to the carotid bulb on the left and right
as previously described [36]. CP was defined as present if
two of the three following conditions were met: (i) a dis-
tinct area of protrusion >50% into the lumen compared
with the surrounding wall; (ii) increased echogenicity; and
(iii) IMT>0.15 cm [37]. Neither assessor was aware of the
vitamin D status of the patient.
Statistical analysis was conducted using STATA v10.0
(StataCorp LP, TX, USA). Differences between vitamin
D-deficient and non-deficient groups were determined
using non-parametric tests (MannWhitney U-test).
Linear and logistic regression models were used to inves-
tigate linear associations between 25(OH)D and markers
of subclinical CVD. For linear regression, aPWV was log
transformed to satisfy assumptions of normality. Logistic
regression was used to analyse binomial variables.
Ethical approval for this study was obtained from the
local research ethics committee (Northwest 5 REC, refer-
ence number 05/MRE08/62) and written consent was ob-
tained in accordance with the Declaration of Helsinki.
Results
Characteristics of patients
We recruited 75 women with SLE. The median [interquar-
tile range (IQR)] age of the study population was
53 (4660) years with a median disease duration of
16 (827) years. Sixty-nine patients (92.0%) were
Caucasian. The majority of the patients had stable disease
with median (IQR) SLEDAI-2000 score of 0 (04).
Thirty-three (51.6%) had a SLEDAI-2000 score of 0.
CSs were being taken by 29/75 (38.7%) patients with a
median (IQR) daily dose of 7.5 (514.5) mg. Anti-malarial
therapy (predominantly HCQ) was being taken by 38/75
(50.7%) patients. Immunosuppressants were used con-
currently in 27/75 (36%) patients; AZA, n=13 (17%);
ciclosporin, n=2 (3%); MMF, n=7 (9%); MTX, n=7
(9%); LEF, n=1 (1%); rituximab, n=1 (1%). The demo-
graphic and disease characteristics of the study popula-
tion are shown in Table 1.
Prevalence of vitamin D deficiency
The median (IQR) 25(OH)D was 19.7 (15.129.6)ng/ml for
the whole population. Thirty-nine (52%) patients were vita-
min D deficient. Serum 25(OH)D levels were higher in the
summer than the winter (24.2 vs 19.3ng/ml), although this
was not statistically significant (P=0.352), and even in the
summer months 25/50 (50%) were vitamin D deficient.
Patients prescribed calcium/vitamin D had no significant
difference in their vitamin D levels and 14/29 (48%) of
those prescribed supplements were vitamin D deficient.
Vitamin D deficiency and SLE disease
Patients with active disease (SLEDAI-2000 54, n=13)
had significantly lower 25(OH)D than those without
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Vitamin D deficiency and vascular stiffness in lupus[12.9 (12.016.2) vs 20.3 (16.230.8)ng/ml, P=0.031] as
shown in Fig. 1. There was no association between serum
vitamin D and anti-dsDNA antibodies or serum C3 or C4
complement. Vitamin D levels did not differ in those pa-
tients receiving CSs or in those with renal impairment
(data not shown).
Vitamin D deficiency and cardiovascular risk factors
Three patients (4%) had ischaemic heart disease as mani-
fest by a history of angina pectoris. Two of these three
patients also reported a previous myocardial infarction.
Only seven (9.7%) patients were current smokers, and
the median (IQR) smoking history for the whole group
was 0.9 (010.8) pack-years. Most patients were over-
weight with a median (IQR) BMI of 26.7 (24.130.5)
kg/m
2. The prevalence of traditional cardiovascular risk
factors is presented in Table 1.
Patients who were vitamin D deficient had significantly
higher BMI [28.7 (24.731.1) vs 25.7 (22.828.1),
P=0.014], fasting serum insulin [12.6 (9.223.4) vs
10.8 (7.813.8) mIU/ml] and insulin resistance [HOMA-IR
1.95 (1.43.2) vs 1.6 (1.21.9), P=0.023] than those with
25(OH)D >20ng/ml. There was no significant association
between serum 25(OH)D and other traditional cardio-
vascular risk factors, although vitamin D deficiency was
associated with a trend towards increased waist circum-
ference, waist:hip ratio and diastolic blood pressure
(Table 2).
Vitamin D deficiency and markers of subclinical CVD
The median (IQR) aPWV in our whole population was
6.2 (3.711.0) m/s. Patients who were vitamin D deficient
had a significantly increased aPWV [8.2 (4.711.6) vs
5.4 (3.38.9), P=0.033]. There was no significant associ-
ation between 25(OH)D deficiency and carotid IMT, CP or
soluble vascular cell adhesion molecules (E-selectin and
VCAM-1) (Table 3).
In a univariate linear regression model, lower serum
25(OH)D was associated with a significantly increased
aPVW [log(aPWV) b (95% CI) 0.021 (0.038, 0.005),
P=0.010] but not CP [odds ratio (95% CI) 1.03 (0.98,
1.08), P=0.205) or cIMT [odds ratio, 575th percentile
TABLE 1 Characteristics of the study population
n (%) or
median (IQR)
Demographics
Female gender 75 (100)
Age, years
a 53.4 (45.8, 60.4)
Ethnicity 69 (92.0)
Caucasian
Afro-Caribbean 1 (1.33)
South Asian 1 (1.33)
South-East Asian 1 (1.33)
Middle Eastern 2 (2.67)
Mixed race 1 (1.33)
Disease characteristics
Disease duration, years
a 16.1 (8.8, 27.3)
SLEDAI score
a 0 (0, 4)
C3, g/l
a 1.07 (0.88, 1.36)
C4, g/l
a 0.2 (0.13, 0.24)
hs-CRP, mg/l
a 3.1 (1.6, 7.0)
Currently receiving steroids 29 (38.6)
Current daily steroid dose, mg
a 7.5 (5, 14.5)
Currently receiving HCQ 38 (50.7)
Currently receiving
immunosuppressants
27 (36.0)
Traditional cardiovascular risk factors
Systolic BP, mmHg
a 125 (116, 140)
Diastolic BP, mmHg
a 71 (66, 77)
Use of anti-hypertensive
medication
24 (32.4)
BMI
a, k/gm
2 26.7 (24.1, 30.5)
Waist : hip ratio
a 0.88 (0.85, 0.93)
eGFR (MDRD)
a, ml/min/1.73m
2 88.2 (71.2, 100.6)
eGFR <60 ml/min/1.73 m
2 8 (10.7)
Total cholesterol, mmol/l
a 4.67 (4.13, 5.36)
HDL cholesterol, mmol/l
a 1.72 (1.44, 2.01)
Serum triglycerides, mmol/l
a 1.11 (0.83, 1.53)
Fasting insulin, mIU/ml
a 11.7 (8.5, 19.3)
HOMA-IR
a 1.7 (1.3, 2.8)
Current smoker 7 (9.7)
Smoking history (pack-years)
a 0.9 (0, 10.8)
History of diabetes mellitus 4 (5.3)
History of any CVD (myocardial
infarction, angina pectoris,
peripheral vascular disease,
transient ischaemic attack,
stroke)
18 (24)
History of ischaemic heart
disease (myocardial infarction,
angina pectoris)
3 (4)
aMedian (IQR).
FIG.1Comparison of 25(OH)D levels according to clinical
disease activity using the SLEDAI-2000. Patients with
more active disease (defined as being within the upper
quartile, corresponding to a SLEDAI score of 54) had
significantly lower 25(OH)D than those with inactive or low
disease activity (P=0.03). Box represents 25th and 75th
percentiles, horizontal line respresents the median,
error bars show the 5th and 95th percentiles, outside
values are shown as dots.
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itional cardiovascular risk factors and serum insulin levels,
this association remained significant [b (95% CI) 0.023
(0.043, 0.003), P=0.021] (Table 4). Adjustment for the
SLEDAI-2000 score reduced the strength of the association
such that it was no longer significant [b (95% CI) 0.012
(0.031, 0.007), P=0.200] (Table 4).
Discussion
This is the first study to demonstrate an association be-
tween 25(OH)D and subclinical CVD in patients with SLE.
Serum vitamin D was inversely associated with aortic stiff-
ness in a linear regression model, but not with either CP or
IMT. This association persisted after adjustment for
TABLE 2 Association between vitamin D deficiency and cardiovascular risk factors
CVD risk factor 25(OH)D 420ng/ml 25(OH)D >20ng/ml P-value
Age, years 52.0 (42.360.4) 54.0 (47.360.35) 0.35
Current smokers, n (%) 5 (14) 2 (6) 0.26
BMI, kg/m
2 28.7 (24.731.1) 25.7 (22.828.1) 0.01
Waist circumference, cm 92.4 (84.5105.9) 87.1 (80.196.9) 0.05
Waist : hip ratio 0.89 (0.850.97) 0.87 (0.8330.91) 0.07
Systolic BP, mmHg 123 (116142) 127.5 (116140) 0.98
Diastolic BP, mmHg 73 (6680) 70.5 (6175) 0.08
Total cholesterol, mmol/l 4.68 (4.135.56) 4.57 (4.15.26) 0.50
HDL cholesterol, mmol/l 1.67 (1.421.975) 1.75 (1.452.015) 0.97
Fasting glucose, mmol/l 4.8 (4.355.2) 4.5 (4.25.1) 0.47
Serum insulin, mIU/ml 12.6 (9.123.4) 10.7 (7.713.8) 0.03
Insulin resistance (HOMA-IR) 1.95 (1.43.2) 1.6 (1.21.9) 0.02
eGFR, ml/min/1.73 m
2 87.6 (64.3101.7) 90.7 (74.7100.6) 0.61
Results are expressed as median (IQR) unless otherwise stated. BP: blood pressure. Statistically significant
results are shown in bold type.
TABLE 4 Vitamin D deficiency and subclinical markers of CVD
aPWV
a CP
b cIMT
c
Model b (95% CI) P OR (95% CI) P OR (95% CI) P
Unadjusted 0.021 (0.038, 0.005) 0.010 1.03 (0.98, 1.08) 0.205 1.02 (0.96, 1.07) 0.571
Adjusted
Model 1
d 0.020 (0.040, 0.0003) 0.047 1.03 (0.97, 1.09) 0.366 1.02 (0.95, 1.09) 0.585
Model 2
e 0.023 (0.043, 0.003) 0.021 1.04 (0.97, 1.11) 0.236 1.02 (0.95, 1.10) 0.561
Model 3
f 0.012 (0.031, 0.007) 0.200 1.03 (0.96, 1.10) 0.382 1.00 (0.92, 1.09) 0.999
aLinear regression of log(aPWV).
bLogistic regression model for the presence of CP.
cLogistic regression model for cIMT above
upper quartile.
dAdjusted for age, season (summer or winter), BMI, systolic blood pressure, pack-years smoking, disease
duration, eGFR, fasting glucose.
eAs Model 1 above plus serum insulin.
fAs Model 1 above plus SLEDAI score. b: b-coeffe-
cient, OR: odds ratio.
TABLE 3 Association between vitamin D deficiency and markers of subclinical CVD
Marker of CVD All subjects
25(OH)D
420ng/ml (n=39)
25(OH)D
>20ng/ml (n=36) P-value
aPWV, m/s 6.2 (3.711.0) 8.2 (4.711.6) 5.4 (3.38.9) 0.03
CP, n (%)
a 35 (51.4) 14 (20.6) 21 (30.8) 0.09
Carotid IMT, mm
a 0.07 (0.060.08) 0.06 (0.050.07) 0.07 (0.060.08) 0.21
VCAM-1, ng/ml 289 (232.3369.1) 265.4 (226.1313.1) 309.65 (245.75389.7) 0.06
E-selectin, ng/ml 10.38 (6.8913.5) 10.38 (7.1412.8) 10.34 (6.5414.15) 0.69
Results are expressed as median (IQR) unless otherwise stated. Statistically significant results are shown in bold
type.
aTotal n=68 (n=34 in each group).
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those of Wu et al. [38], who also found no association
between vitamin D and CP or IMT.
Increased arterial stiffness, as measured by aPWV, pre-
dicts cardiovascular outcomes in the general population.
A recent meta-analysis of 17 studies revealed that a 1m/s
increase in aPWV can increase the risk of a cardiovascular
event by 14% [39]. In our study, the difference in median
aPWV between the vitamin D-deficient and -replete
groups was 2.8m/s. This suggests that vitamin D defi-
ciency may significantly increase the risk of future CVD
within the lupus population.
Vascular stiffness can be partly driven by inflammation,
and better disease control in patients with inflammatory
arthritis results in a reduction in pulse wave velocity [40].
Selzer et al. [41] noted that inflammatory biomarkers in
SLE were particularly associated with aPWV. In our study,
the association between 25(OH)D and stiffness was at
least in part accounted for by disease activity since in a
regression model that includes SLEDAI score the associ-
ation was no longer significant.
Patients with more active disease (SLEDAI score in the
upperquartileoftherange)hadsignificantlylower25(OH)D.
There was no association, however, between 25(OH)D and
serum C3 and C4 complement or anti-dsDNA titre.
Furthermore, there was no association between 25(OH)D
and use of immunosuppressants, anti-malarials or CSs.
The precise mechanism by which this association may
be mediated requires further study.
Our results suggest that the association between
25(OH)D and disease activity is strongest in those patients
with the most active disease/lowest vitamin D. Given that
90% of vitamin D is synthesised in ultraviolet (UV) light-
exposed skin, sunlight avoidance may contribute signifi-
cantly to the association between D and disease activity.
Photosensitivity is a common feature of SLE and the use
of high-factor sun block is a mainstay of conservative
management. Patients with active disease may also be
less inclined to spend time outdoors due to feeling
unwell, an example of reverse causality.
Vitamin D has, however, been shown to have important
roles in the regulation of the inflammatory response.
In vitro studies have shown that the active metabolite of
vitamin D can modulate the inflammatory response by
driving a Th1 cell response towards a Th2 response via
inhibition of Th1 cell proliferation, reducing the production
of inflammatory cytokines (IL-2 and IFN-g), and the induc-
tion of regulatory T cells [4244]. Furthermore, autoanti-
body production from peripheral blood mononuclear cells
isolated from patients with SLE is inhibited by vitamin D
[45]. Vitamin D deficiency may therefore augment the in-
flammatory response in SLE, underpinning both increased
disease activity and vascular stiffness.
Insulin resistance (elevated serum insulin and HOMA-IR)
and obesity were the only traditional cardiovascular risk
factors to be significantly associated with vitamin D
status. Increased BMI and insulin resistance have been
associated with 25(OH)D in other studies of both adults
and adolescents with SLE [37, 38] and within the general
population [4648]. We have shown, however, that aPWV
was associated with vitamin D independently of either
BMI or serum insulin levels.
Vitamin D deficiency was common in our population of
patients with established SLE [52% of patients had serum
25(OH)D <20ng/ml]. This confirms the findings of others,
although a direct comparison of serum 25(OH)D between
studies is difficult due to variation in the study popula-
tions, study location and perhaps more importantly, in
the methods used to measure vitamin D. In patients with
SLE, mean levels of 25(OH)D have been reported from
11.5 to 44.6ng/ml between different studies. Regardless
of the absolute serum values reported, levels of vitamin D
areinvariablylowerinSLEpatientsthanincontrols[1619].
Our study is limited by a relatively small study popula-
tion and may therefore lack power to identify other asso-
ciations between vitamin D and risk factors for CVD.
Patients with vitamin D deficiency had a trend towards
increased diastolic blood pressure, central obesity, lower
HDL cholesterol and renal impairment, although none
of these parameters reached statistical significance.
Although an association was seen between aPWV and
25(OH)D following adjustment for season and traditional
risk factors, we did not adjust for ethnicity in this study.
Indo-Asians and Afro-Caribbeans have more severe SLE
[49, 50], and in the general population, these ethnicities
are also associated with lower vitamin D concentrations
[51, 52]. Whether the relationship between vitamin D and
vascular disease differs in these subgroups beyond its
influence on lupus disease activity cannot be answered
in this study. A larger study will be needed to examine
whether the relationships we have noted varies in different
ethnic subgroups. Furthermore, due to the cross-sectional
design of the study, only the 25(OH)D status at the time of
assessment was measured.
Others have found no association between vitamin D
and subclinical CVD in patients with SLE and our results
are in apparent contradiction to this [38]. In this context, it
is, however, important to consider temporal differences in
the development of vascular stiffness compared with ca-
rotid IMT/plaque. Whereas atherosclerosis develops
slowly over a period of many years, vascular stiffness is
a dynamic process that can change in response to ther-
apy over a relative short period of time [40]. A single
measurement of 25(OH)D is unlikely to reflect its contribu-
tion to the development of increased IMT, which occurs
over many years, resulting in an apparent lack of associ-
ation. Furthermore, different risk factors appear to be
associated with the development and progression of
aPWV, CP and cIMT [41, 53, 54], suggesting different
pathological processes. It could be concluded that our
observations of aPWV reflect the study of an earlier and
more dynamic pathological process than either CP or
cIMT, and that aPWV may therefore be more responsive
to current vitamin D status.
Conclusions
Vitamin D deficiency is common in SLE and is associated
with vascular stiffness independently of traditional
548 www.rheumatology.oxfordjournals.org
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is a strong inverse association between vitamin D defi-
ciency and lupus disease activity which may, in part,
drive this process in vitamin D deficient patients (Fig. 2).
Prospective interventional studies and randomized con-
trolled trials should focus on the effect of treating vitamin
D deficiency on both SLE disease activity and vascular
stiffness.
Rheumatology key messages
. Vitamin D deficiency is common in patients with
SLE and is associated with increased disease
activity.
. Lower vitamin D is associated with increased aortic
stiffness in patients with SLE.
. Increased disease activity may mediate the associ-
ation between vitamin D deficiency and vascular
stiffness.
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